An IGF-1 LR3 vial contains 10mg of lyophilized Long Arg3 Insulin-Like Growth Factor-1, a synthetic 83-amino-acid analog engineered for extended half-life in cellular and animal research models. Designed specifically for in vitro cell culture assays and preclinical signaling investigations, each IGF-1 LR3 vial supplied by PX1 Research undergoes rigorous HPLC mass spectrometry validation to guarantee >98% purity and low endotoxin levels.
An IGF-1 LR3 vial contains 10mg of lyophilized Long Arg3 Insulin-Like Growth Factor-1, a synthetic 83-amino-acid analog engineered for extended half-life in cellular and animal research models. Designed specifically for in vitro cell culture assays and preclinical signaling investigations, each IGF-1 LR3 vial supplied by PX1 Research undergoes rigorous HPLC mass spectrometry validation to guarantee >98% purity and low endotoxin levels.
Long Arg3 Insulin-Like Growth Factor-1 (IGF-1 LR3) is one of the most widely studied synthetic growth factor analogs in contemporary molecular biology and biochemistry. Engineered by replacing the glutamic acid at position 3 with arginine and appending a 13-amino-acid extension sequence to the N-terminus, this 83-amino-acid polypeptide exhibits significantly lower affinity for IGF-binding proteins (IGFBPs) compared to native IGF-1.
When evaluating an IGF-1 LR3 vial for laboratory research, investigators prioritize sequence accuracy, thermal stability, and low endotoxin content. Because native IGF-1 is rapidly sequestered and inactivated by circulating IGFBPs in biological matrix assays, the structural modifications in IGF-1 LR3 permit sustained interaction with the type 1 IGF receptor (IGF-1R). This extended signaling window makes the compound a crucial tool in studies investigating mitogenesis, protein translation cascades, and cellular differentiation across diverse cell lines.
Native mammalian IGF-1 is a 70-amino-acid single-chain polypeptide with three intra-chain disulfide bonds. In contrast, the recombinant design housed within an IGF-1 LR3 vial alters both molecular weight and physiological behavior. The substitution of Glutamic Acid (Glu) with Arginine (Arg) at position 3 introduces a distinct steric hindrance and charge alteration at the primary binding epitope responsible for associating with IGFBP-1 through IGFBP-6.
In addition to the Arg3 mutation, the 13-amino-acid N-terminal extension sequence (MFPAMPLLSLFVN) increases the total molecular mass of the peptide to approximately 9,111 Da. In vitro competitive binding assays demonstrate that while native IGF-1 binds IGFBPs with nanomolar affinity, IGF-1 LR3 exhibits an affinity reduction of greater than 100-fold. Consequently, free molecular concentrations remain substantially higher in cell culture media, allowing researchers to evaluate unhindered IGF-1R receptor dynamics without the confounding variables of binding protein interference.
To select the appropriate tool for growth factor research, laboratory investigators often compare IGF-1 LR3 against other peptides within the insulin-like and somatotropic signaling axes. While an IGF-1 LR3 vial provides a sustained, systemic model of IGF-1R activation due to its low IGFBP affinity, DES IGF-1 lacks the N-terminal tripeptide (Gly-Pro-Glu), making it up to ten times more potent in vitro specifically in acidic extracellular environments, albeit with a drastically shorter localized half-life.
Furthermore, researchers studying tissue-repair cascades and satellite cell proliferation frequently compare downstream growth factors with upstream secretagogues. For instance, PEG-MGF acts via a distinct splice variant pathway focused on myoblast stem cell activation, whereas secretagogues such as CJC-1295 or GHRP-6 stimulate endogenous pituitary growth hormone release. Understanding these mechanistic variances allows primary investigators to construct precise, multi-variable protocols using PX1's comprehensive catalog of research-grade peptides.
In vitro models utilizing the compound from an IGF-1 LR3 vial demonstrate robust autophosphorylation of the IGF-1R transmembrane receptor tyrosine kinase. Upon ligand binding, the receptor undergoes conformational changes that recruit insulin receptor substrate (IRS) proteins, initiating two primary canonical intracellular cascades: the Phosphoinositide 3-Kinase (PI3K)/Akt pathway and the Mitogen-Activated Protein Kinase (MAPK)/Extracellular Signal-Regulated Kinase (ERK) pathway.
Preclinical data indicate that phosphorylation of Akt leads to downstream activation of mammalian target of rapamycin complex 1 (mTORC1) and p70S6 kinase, key drivers of ribosomal biogenesis and de novo protein synthesis. Concurrently, activation of the MAPK/ERK signaling axis governs transcriptional networks responsible for cell cycle progression and cellular survival. Research laboratories utilizing growth factor peptides rely on the stability and consistent purity of PX1's compounds to produce reproducible Western blot, ELISA, and flow cytometry datasets.
Laboratory results depend directly on reagent quality and lot-to-lot consistency. PX1 Research adheres to stringent manufacturing and analytical validation protocols for every IGF-1 LR3 vial distributed to academic, government, and private biotechnology institutions. All production occurs in cGMP-compliant facilities located in the United States, utilizing advanced solid-phase peptide synthesis (SPPS) and liquid-phase purification technologies.
To ensure uncompromising quality, each production lot undergoes rigorous multi-tier verification at an independent ISO 17025 accredited laboratory. Researchers receive full transparency through a lot-specific Certificate of Analysis (COA) containing double-verified data:
• High-Performance Liquid Chromatography (RP-HPLC): Confirms peptide purity levels exceeding 98.0%, ensuring the absence of truncated sequences or synthesis side products. • Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS): Verifies exact theoretical molecular mass and sequence integrity. • Chromogenic LAL Endotoxin Testing: Guarantees endotoxin levels below strictly enforced laboratory thresholds (<0.01 EU/μg), protecting sensitive cell culture lines from lipopolysaccharide (LPS)-induced toxicity. • Lot Traceability & Same-Day Shipping: Every vial is serialized and shipped same-day (Monday through Friday) directly from temperature-controlled facilities in California and Arizona.
Proper preparation of a lyophilized IGF-1 LR3 vial is essential to preserve secondary structure and prevent protein aggregation. Reconstitution procedures must strictly occur within a certified laminar flow hood utilizing sterile aseptic techniques.
Because IGF-1 LR3 contains hydrophobic domains, direct reconstitution into neutral pH saline or pure water can lead to adhesion to glass walls or precipitation out of solution. Standard analytical protocols recommend initial solubilization in a dilute acid solution, such as 10mM to 100mM sterile acetic acid (pH 2.5 to 3.0), to achieve a stable stock concentration (e.g., 1 mg/mL). Once fully dissolved, the stock solution can be further diluted into phosphate-buffered saline (PBS) containing 0.1% Bovine Serum Albumin (BSA) or Human Serum Albumin (HSA) as a carrier protein to prevent non-specific adsorption. For labs requiring specific solvents or stock buffers, detailed technical sheets are available through our reconstitution reagents resource center.
Lyophilized peptide stability varies significantly based on moisture content, storage temperature, and exposure to light. Unopened, lyophilized material inside a sealed PX1 IGF-1 LR3 vial remains stable for up to 24 months when stored in a desiccated freezer at -20°C to -80°C.
Once reconstituted in an acidic stock solution, aliquots should be divided into single-use microcentrifuge tubes to prevent repeated freeze-thaw cycles, which induce shear stress and peptide denaturation. Reconstituted acidic stock solutions stored at 2°C to 8°C typically retain analytical potency for up to 21 to 30 days. For long-term storage of reconstituted aliquots, storing at -80°C in the presence of a carrier protein (0.1% BSA) is recommended. Researchers managing high-throughput facility pipelines can set up recurring shipments through PX1's bulk research accounts program.
In vitro and animal models using the peptide from an IGF-1 LR3 vial span multiple disciplines within biological science. Key areas of investigation include:
1. Skeletal Muscle Regeneration: Investigating myoblast proliferation, satellite cell activation, and myotube hypertrophy in C2C12 cell culture models. 2. Cartilage and Bone Research: Assessing chondrocyte extracellular matrix synthesis, proteoglycan production, and osteoblast differentiation pathways. 3. Neurobiology: Researching neuroprotective signaling, axonal sprouting, and anti-apoptotic survival pathways in primary neuronal cultures exposed to oxidative stress. 4. Metabolic and Endocrine Assays: Analyzing glucose transport uptake mechanisms and lipid metabolism independent of classic insulin receptor engagement.
What is the primary function of an igf-1 lr3 vial in laboratory research?
An IGF-1 LR3 vial contains 10mg of highly purified Long Arg3 IGF-1, a recombinant analog designed for in vitro cell culture and preclinical animal models. It is utilized by researchers to study IGF-1R receptor signaling, protein synthesis pathways (PI3K/Akt/mTOR), cellular proliferation, and myogenesis without binding interference from endogenous IGF-binding proteins.
How does the Arg3 mutation in IGF-1 LR3 alter its binding affinity?
The substitution of Glutamic Acid with Arginine at position 3, combined with a 13-amino-acid N-terminal extension, significantly reduces the peptide's affinity for IGF-binding proteins (IGFBPs) by over 100-fold. This allows free IGF-1 LR3 to remain active in culture media, facilitating prolonged activation of the IGF-1 receptor.
What purity levels are guaranteed for each PX1 IGF-1 LR3 vial?
PX1 Research guarantees a minimum peptide purity of >98.0% as determined by Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Mass Spectrometry (MS). Each lot includes a downloadable Certificate of Analysis (COA) detailing purity, molecular mass, and endotoxin parameters.
What is the endotoxin limit for PX1's IGF-1 LR3 vials?
All PX1 research peptides undergo rigorous kinetic chromogenic LAL assays to ensure endotoxin levels remain below <0.01 EU/μg. Low endotoxin content is critical to prevent inflammatory artifact signaling or cytotoxicity in sensitive cell lines.
How should an IGF-1 LR3 vial be reconstituted for analytical assays?
Laboratory standards recommend initial reconstitution in sterile 10mM–100mM acetic acid (pH 2.5–3.0) to achieve a stable concentrated stock (e.g., 1 mg/mL). Once fully dissolved, stock solutions can be diluted into working buffers like PBS containing 0.1% BSA to prevent peptide adherence to microplate walls.
What are the recommended storage conditions for lyophilized and reconstituted IGF-1 LR3?
Lyophilized vials should be stored desiccated at -20°C to -80°C for up to 24 months. Reconstituted acidic stock solutions should be aliquoted and stored at 2°C to 8°C for short-term use (up to 30 days) or -80°C for long-term storage to avoid degradation from freeze-thaw cycles.
How does IGF-1 LR3 compare to DES(1-3) IGF-1 in research applications?
IGF-1 LR3 features a prolonged biological half-life due to its 13-amino-acid extension and reduced IGFBP affinity, making it ideal for continuous systemic incubation studies. DES(1-3) IGF-1 lacks the N-terminal tripeptide and exhibits enhanced local potency in acidic environments but possesses a much shorter half-life.
Where are PX1 research peptides manufactured and shipped from?
All PX1 peptides are synthesized in cGMP-compliant facilities in the United States. Orders are dispatched with same-day shipping (Monday through Friday) directly from fulfillment centers in California and Arizona.
Can IGF-1 LR3 vials be purchased for human consumption or clinical use?
No. All products offered by PX1 Research, including every IGF-1 LR3 vial, are strictly engineered for laboratory research use only (in vitro and preclinical animal models). They are not intended for human or animal therapeutic, diagnostic, or clinical application.
Does PX1 offer institutional pricing for bulk analytical orders?
Yes. Universities, contract research organizations (CROs), and biotechnology firms requiring high-volume orders or recurring lot allocations can apply for institutional pricing through our wholesale lab accounts portal.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.